Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Phase I Study of Autologous T Cells Engineered to Express Anti-EX02 Chimeric Antigen Receptor (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

NCT06196658 is registered in ClinicalTrials.gov with Zhang Xiaofeng,MD as lead sponsor.

NCT NCT06196658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06196658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Phase I Study of Autologous T Cells Engineered to Express Anti-EX02 Chimeric Antigen Receptor (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer
Lead sponsor
Zhang Xiaofeng,MD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 1, 2024
Completion date
December 31, 2027
Enrollment
6 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary cancer, pancreatic cancer